Home

Arie Belldegrun

CIK 1296549 · Chairman, President and CEO · last filed 2026-06-24

Arie Belldegrun is a Chairman, President and CEO who has filed 75 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for URGN, was dated Jun 24, 2026. Across all open-market trades the lifetime net is +$14.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $23.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$23.41M

Companies

9

Total Filings

75

Lifetime Open-Market Net

$14.95M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
URGN Director 408,693 $40.88 $16.71M $0 13 2026-06-24
ALLO Director 4,034,979 $1.66 $6.70M $17.96M 18 2026-02-04
Kronos Bio, Inc. (KRON) Delisted Director 0 $0.88 $0 $0 6 2025-06-20
Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted Director 694,925 $0.01 $4.4K $0 3 2024-06-14
Kite Pharma, Inc. (KITE) Delisted Chairman, President and CEO 609,160 — — -$3.75M 7 2017-09-27
CAPRICOR THERAPEUTICS, INC. (NLTXW) Delisted Director 292,000 — — $0 2 2011-05-12
CAPRICOR THERAPEUTICS, INC. (NLTX) Delisted Director 324 $13.96 $4.5K $0 1 2009-09-28
Cougar Biotechnology, Inc. (CGRB) Delisted Director 0 — — $727.5K 5 2009-07-07
Talon Therapeutics, Inc. (HNAB) Delisted Director 0 — — $0 2 2009-02-26

Recent Filings

75 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 URGN Grant (A) — $0 EDGAR
2026-02-04 ALLO Grant (A) — $0 EDGAR
2025-08-27 URGN Grant (A) — $0 EDGAR
2025-06-20 Kronos Bio, Inc. (KRON) Delisted Mixed −3,444,889 -$1.96M EDGAR
2025-01-28 ALLO Grant (A) +369,957 $0 EDGAR
2024-08-08 URGN Grant (A) — $0 EDGAR
2024-06-26 Kronos Bio, Inc. (KRON) Delisted Grant (A) — $0 EDGAR
2024-06-14 Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted Mixed +105,263 $0 EDGAR
2024-05-20 ALLO Mixed +2,068,965 $6.00M EDGAR
2024-01-31 ALLO Grant (A) +211,973 $0 EDGAR
Showing 1–10 of 75
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.